GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Financial Strength

Xtant Medical Holdings (Xtant Medical Holdings) Financial Strength : 5 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Financial Strength?

Xtant Medical Holdings has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Xtant Medical Holdings did not have earnings to cover the interest expense. Xtant Medical Holdings's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.21. As of today, Xtant Medical Holdings's Altman Z-Score is -0.28.


Competitive Comparison of Xtant Medical Holdings's Financial Strength

For the Medical Devices subindustry, Xtant Medical Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Financial Strength distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Financial Strength falls into.



Xtant Medical Holdings Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Xtant Medical Holdings's Interest Expense for the months ended in Dec. 2023 was $-0.82 Mil. Its Operating Income for the months ended in Dec. 2023 was $-3.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.04 Mil.

Xtant Medical Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is

Xtant Medical Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Xtant Medical Holdings's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.517 + 18.042) / 112.432
=0.21

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Xtant Medical Holdings has a Z-score of -0.28, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -0.28 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xtant Medical Holdings  (AMEX:XTNT) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Xtant Medical Holdings has the Financial Strength Rank of 5.


Xtant Medical Holdings Financial Strength Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Traded in Other Exchanges
Address
664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Executives
Kevin D Brandt officer: VP & Chief Commercial Officer 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller director 664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson director 664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils officer: Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger officer: Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne officer: President and CEO 664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis director 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen officer: VP, Finance and Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin officer: VP & Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen officer: SVP Fiance & Admin. & CFO 664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750

Xtant Medical Holdings (Xtant Medical Holdings) Headlines

From GuruFocus